Measles-mumps-rubella vaccine that is given in the second year of life is associated with an increased risk of immune thrombocytopenia purpura. - GreenMedInfo Summary
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
Pediatrics. 2008 Mar;121(3):e687-92. PMID: 18310189
Department of Preventive Medicine, Kaiser Pemanente Colorado, Denver, CO 80231, USA. [email protected]
BACKGROUND: The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies. METHODS: By using the Vaccine Safety Datalink, we identified measles-mumps-rubella-vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of